Prometrium Global Regulatory Status

FDA Approval History and Original NDA

The FDA approved Prometrium on September 30, 1998, under NDA 020843. Solvay Pharmaceuticals submitted the original application based on two clinical programs: one for secondary amenorrhea and another for endometrial protection during postmenopausal estrogen therapy. The approval made Prometrium the first oral micronized progesterone product available in the United States [1].

The amenorrhea indication was supported by a 10-day dosing regimen of 400 mg nightly. For endometrial protection, the approved dose was 200 mg nightly for 12 consecutive days per 28-day cycle in women receiving daily conjugated estrogens 0.625 mg. The endometrial hyperplasia program drew on findings from the PEPI trial (Postmenopausal Estrogen/Progestin Interventions), a multicenter, randomized, placebo-controlled study published in JAMA in 1995. PEPI enrolled 875 postmenopausal women across 7 clinical centers and demonstrated that micronized progesterone 200 mg/day for 12 days per cycle prevented endometrial hyperplasia as effectively as medroxyprogesterone acetate (MPA) 10 mg/day, while producing a significantly better effect on HDL cholesterol [2]. The Writing Group for the PEPI Trial noted: "Micronized progesterone did not significantly reduce the beneficial effects of estrogen on HDL-C, in contrast to MPA" [2].

Solvay later became part of Abbott Laboratories in 2010, and the Prometrium brand transferred to AbbVie when Abbott split in 2013. AbbVie remains the NDA holder today [1].

Current US Prescribing Label and Boxed Warning

The Prometrium label contains a boxed warning that applies to all estrogen-plus-progestin combination therapies. This warning language is a direct consequence of the Women's Health Initiative (WHI) findings published in 2002.

The boxed warning states that estrogen plus progestin therapy should not be used for prevention of cardiovascular disease or dementia, and that the combination increases risks of myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, invasive breast cancer, and probable dementia in women aged 65 and older [3]. A critical distinction: the WHI used MPA 2.5 mg daily (Prempro), not micronized progesterone. The FDA applied the warning as a class effect to all progestin-containing products regardless of formulation.

The label lists the most common adverse reactions from clinical trials as somnolence (27% at 200 mg, 37% at 300 mg), dizziness (15% at 200 mg, 27% at 300 mg), headache (13% at 200 mg, 17% at 300 mg), and abdominal distension (8% at 200 mg, 10% at 300 mg) [3]. These events are largely attributable to progesterone's metabolite allopregnanolone, a potent GABA-A receptor modulator. The label recommends bedtime dosing to mitigate somnolence.

A peanut allergy contraindication is prominently included because the capsule vehicle is peanut oil. Patients with known peanut hypersensitivity cannot use the branded formulation. Some generic versions use alternative oils [3].

International Regulatory Approvals

Micronized progesterone predates Prometrium's US approval by decades in France. Laboratoires Besins-Iscovesco (now Besins Healthcare) introduced Utrogestan in France in the 1980s, and the Agence Nationale de Sécurité du Médicament (ANSM) has maintained its authorization continuously since then [4]. Utrogestan is approved in both 100 mg and 200 mg capsule strengths, with an additional vaginal route of administration that the US oral-only label does not include.

Health Canada approved Prometrium in 1995, three years before the FDA. The Canadian product monograph carries similar cardiovascular and breast cancer warnings but follows the Health Canada risk communication framework rather than the FDA boxed warning format [5].

Australia's Therapeutic Goods Administration (TGA) lists micronized progesterone under the brand name Prometrium on the Australian Register of Therapeutic Goods (ARTG). The TGA-approved indications mirror the US label. Registration details are publicly searchable through the ARTG database.

In the European Union, micronized progesterone does not hold a centralized EMA marketing authorization. Instead, it is approved through national procedures in individual member states. France, Belgium, Italy, Spain, Portugal, and several other EU countries authorize it under the Utrogestan brand or local generics. The absence of a centralized procedure means there is no single EMA European Public Assessment Report (EPAR) for micronized progesterone, a point that sometimes causes confusion when clinicians search the EMA database.

Beyond these major markets, micronized progesterone holds marketing authorizations in over 40 countries spanning Latin America, Asia-Pacific, the Middle East, and Africa. Brand names vary by region.

The WHI Class-Label Controversy

No regulatory topic around Prometrium generates more clinical debate than the application of WHI-derived warnings to micronized progesterone. The core issue is straightforward: the WHI tested a different drug.

The WHI estrogen-plus-progestin arm used continuous combined conjugated equine estrogens (CEE) 0.625 mg plus MPA 2.5 mg daily in 16,608 postmenopausal women. After a mean follow-up of 5.6 years, the hazard ratio for invasive breast cancer was 1.26 (95% CI 1.00 to 1.59). The hazard ratio for coronary heart disease was 1.29 (95% CI 1.02 to 1.63) [6]. These results applied specifically to CEE + MPA.

The E3N French cohort study, which followed 80,377 postmenopausal women for a mean of 8.1 years, found no increased breast cancer risk with estrogen combined with micronized progesterone (RR 1.00 to 95% CI 0.83 to 1.22), while estrogen plus synthetic progestins showed a significantly elevated risk (RR 1.69 to 95% CI 1.50 to 1.91) [7]. The Endocrine Society's 2015 Scientific Statement on menopausal hormone therapy acknowledged these differential risk profiles but stopped short of recommending removal of the class-wide warning [8].

The FDA's position remains that available randomized controlled trial evidence does not yet demonstrate that micronized progesterone produces cardiovascular or breast cancer outcomes different from those seen with synthetic progestins. The agency has not required or received a dedicated large-scale RCT comparing micronized progesterone against MPA for these endpoints. Until such a trial is completed, the class-wide boxed warning persists.

Dr. JoAnn Manson, principal investigator of the WHI, stated in a 2020 JAMA editorial: "The type of progestogen matters, and the WHI results should not be extrapolated to all progestogens" [9].

Generic Approvals and Market Access

The first generic micronized progesterone capsules received FDA approval through the ANDA pathway in 2012, when the Orange Book exclusivity period expired. Multiple manufacturers now produce generic versions, including Teva Pharmaceuticals, Mylan (now Viatris), and Sun Pharmaceutical.

Generic competition reduced the average wholesale price significantly. Branded Prometrium carries a list price of approximately $300 to $400 for a 30-count supply of 200 mg capsules, while generic equivalents typically cost $15 to $50 at retail pharmacies with insurance or discount programs [1]. This price differential makes micronized progesterone one of the more affordable hormonal therapies available.

The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) rates the generic versions as "AB"-rated to the reference listed drug, meaning they are considered therapeutically equivalent and substitutable at the pharmacy level [1].

One practical note for prescribers: not all generics use peanut oil. Some ANDA holders use sunflower oil or other vehicles. Patients with peanut allergy should confirm the inactive ingredient list of their specific generic product with the dispensing pharmacist.

Post-Market Safety Surveillance

The FDA Adverse Event Reporting System (FAERS) and the Sentinel System provide ongoing post-market surveillance for Prometrium and its generics. No unique safety signals have emerged for micronized progesterone beyond those expected for the progestin class.

The Sentinel System, the FDA's active surveillance program covering over 100 million patients through electronic health records, has been used to evaluate hormone therapy outcomes including venous thromboembolism (VTE). A 2018 Sentinel analysis of VTE risk with hormone therapy products found that oral estrogen-progestin combinations carried higher VTE rates than transdermal formulations, consistent with the hepatic first-pass effect of oral estrogens rather than the progestin component specifically [10].

FAERS data through 2025 show that the most frequently reported adverse events for micronized progesterone remain somnolence, dizziness, headache, and breast tenderness. Serious reports are rare and predominantly consist of thromboembolic events in patients also taking oral estrogen, making attribution to the progestin component difficult [10].

Post-market requirements from the original NDA remain active. AbbVie participates in ongoing pharmacovigilance reporting as part of standard FDA post-marketing commitments.

Regulatory Differences in Route of Administration

A significant regulatory divergence exists between the US and most other markets regarding vaginal use. In France, the Utrogestan label explicitly includes vaginal administration. The French prescribing information provides vaginal dosing for luteal phase support in assisted reproduction and for progesterone supplementation in early pregnancy. Many European practitioners prescribe micronized progesterone vaginally as standard practice [4].

In the United States, the Prometrium label only covers oral administration. The capsules are the same physical product, and US physicians do prescribe them vaginally off-label with considerable frequency. The American Society for Reproductive Medicine (ASRM) practice guidelines reference vaginal micronized progesterone as a first-line option for luteal support in IVF cycles [11]. This creates an unusual situation: off-label vaginal use is the standard of care in reproductive endocrinology, yet the FDA-approved label does not address it.

Crinone (progesterone vaginal gel, 8%) and Endometrin (progesterone vaginal insert, 100 mg) are separate FDA-approved products designed specifically for vaginal delivery of progesterone. Their existence may partly explain why AbbVie has not pursued a supplemental NDA for vaginal Prometrium.

Ongoing Regulatory Developments

Several regulatory developments may affect micronized progesterone's status in coming years. The REPLENISH trial (NCT01942668), a Phase 3 study of TX-001HR (a combination of estradiol and micronized progesterone in a single capsule), led to FDA approval of Bijuva in October 2018. Bijuva's approval represented the first combination product containing micronized progesterone and bioidentical 17-beta estradiol [12].

Bijuva's labeling carries the same class-wide boxed warning as Prometrium, but its approval pathway required new endometrial safety and vasomotor efficacy data that further confirmed micronized progesterone's endometrial protective effect at the 100 mg dose when combined with estradiol 1 mg.

The European Menopause and Andropause Society (EMAS) 2021 position statement recommended micronized progesterone as the preferred progestogen for endometrial protection based on its metabolic and breast safety profile [13]. While position statements do not directly change regulatory labels, they influence prescribing patterns and may support future regulatory submissions for label modifications.

No active FDA citizen petition or supplemental NDA currently seeks to differentiate the Prometrium boxed warning from synthetic progestins. Such a change would likely require a prospective, randomized, event-driven trial with breast cancer or cardiovascular disease as primary endpoints, a study that would need to enroll tens of thousands of women and run for years. The cost and logistic challenges of such a trial make it unlikely to be industry-sponsored for a now-generic product.

Micronized progesterone 200 mg at bedtime for 12 days per 28-day cycle remains the FDA-approved regimen for endometrial protection, and current Endocrine Society and NAMS guidelines continue to list it as a first-line progestogen option for menopausal hormone therapy [8].